Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Delivers Strong Quarter On Ocrevus Launch, Pipeline Promise

Executive Summary

Roche's strong first quarter and promising array of innovative medicines left investors wondering why it didn't also lift its financial guidance for the year.

You may also be interested in...



Roche's Neuroscience Franchise Gets Lift From Huntington's Breakthrough

Roche is aiming to bolster its future neuroscience franchise with another potential breakthrough product in neurology to add to its clinical-stage efforts in Alzheimer's disease, and its success in developing the first therapy for primary progressive multiple sclerosis, Ocrevus.

Roche Lifts Outlook, Spotlights Perjeta To Drive Growth

A “phenomenal” start by Ocrevus and the use of two other newly launched medicines, Tecentriq and Alecensa, drove sales growth at Roche in the first half of 2017 – with the previously cautious company now upgrading its financial outlook for the year and expecting further growth from breast cancer therapy Perjeta.

Laquinimod Prospects Seen Small After RRMS CONCERTO Trial Failure

Teva has no current plans to further pursue laquinimod in relapsing-remitting multiple sclerosis after the investigational asset, developed by Sweden's Active Biotech, failed in the CONCERTO Phase III trial.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel